menu
    • menu

    Company profile for NovelMed Therapeutics

    NEW Drugs in Dev: 4
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NovelMed is a cutting edge clinical-stage biotech We are a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting chronic diseases with large market potential and unmet medical need.NovelMed Th...
    NovelMed is a cutting edge clinical-stage biotech We are a privately-held biotechnology company developing novel therapies for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting chronic diseases with large market potential and unmet medical need.NovelMed Therapeutics is a privately held biotechnology company that has developed cutting-edge highly selective therapeutics for complement-mediated diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NovelMed TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11000 Cedar Avenue Cleveland, Ohio 44106
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novelmed.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AACR Annual meeting

    AACR Annual meeting

    Not Confirmed

    envelop Contact Supplier

    AACR Annual meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Clears NovelMed's SC Ruxoprubart for PNH on Phase II Data
    FDA Clears NovelMed's SC Ruxoprubart for PNH on Phase II Data

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251828/0/en/NovelMed-Therapeutics-Announces-Regulatory-Clearance-for-Subcutaneous-Ruxoprubart-and-Reports-Positive-Phase-II-Intravenous-Monotherapy-Results-in-PNH.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Ruxoprubart Shows Best-in-Class Efficacy in PNH Phase II Trial
    Ruxoprubart Shows Best-in-Class Efficacy in PNH Phase II Trial

    19 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/19/3083995/0/en/Phase-II-Data-in-Treatment-Na%C3%AFve-Paroxysmal-Nocturnal-Hemoglobinuria-PNH-Patients-Ruxoprubart-Demonstrates-Best-in-Class-Efficacy-as-Monotherapy.html

    GLOBENEWSWIRE
    19 May 2025
    Share Share
    US FDA approves NM8074 (Ruxoprubart) IND for treating Dermatomyos
    US FDA approves NM8074 (Ruxoprubart) IND for treating Dermatomyos

    24 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/24/3031279/0/en/United-States-FDA-Approves-NM8074-Ruxoprubart-IND-for-Treating-Dermatomyositis-DM-A-Chronic-Inflammatory-Disorder-of-the-Skin.html

    GLOBENEWSWIRE
    24 Feb 2025
    Share Share
    FDA Approves Phase II Clinical Trial For Ruxoprubart In ANCA Vasculitis
    FDA Approves Phase II Clinical Trial For Ruxoprubart In ANCA Vasculitis

    17 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/17/2899645/0/en/FDA-Approves-Phase-II-Clinical-Trial-for-Ruxoprubart-in-ANCA-Associated-Vasculitis-AAV-a-Chronic-Rare-Disease-in-Nephrology.html

    GLOBENEWSWIRE
    17 Jun 2024
    Share Share
    FDA Grants NM5072 Orphan Status For PNH Treatment
    FDA Grants NM5072 Orphan Status For PNH Treatment

    15 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/15/2862778/0/en/The-United-States-FDA-Awards-Orphan-Drug-Designation-ODD-to-NM5072-for-Treating-Paroxysmal-Nocturnal-Hemoglobinuria-PNH.html

    GLOBENEWSWIRE
    15 Apr 2024
    Share Share
    Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for PNH Treatment
    Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for PNH Treatment

    12 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/12/2827525/0/en/Ruxoprubart-NM8074-Scores-FDA-Orphan-Drug-Designation-for-Paroxysmal-Nocturnal-Hemoglobinuria-PNH-Treatment.html

    GLOBENEWSWIRE
    12 Feb 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search